Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125


Advances in the study of HLA-restricted epitope vaccines.

Zhao L, Zhang M, Cong H.

Hum Vaccin Immunother. 2013 Dec;9(12):2566-77. doi: 10.4161/hv.26088. Epub 2013 Aug 16. Review.


A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.

Oyarzun P, Ellis JJ, Gonzalez-Galarza FF, Jones AR, Middleton D, Boden M, Kobe B.

Vaccine. 2015 Mar 3;33(10):1267-73. doi: 10.1016/j.vaccine.2015.01.040. Epub 2015 Jan 25.


Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice.

Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, El Bissati K, Zhou Y, Suzuki Y, Lee D, Woods S, Sommerville C, Henriquez FL, Roberts CW, McLeod R.

Hum Immunol. 2012 Jan;73(1):1-10. doi: 10.1016/j.humimm.2011.10.006. Epub 2011 Oct 12.


A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.

Chentoufi AA, Dasgupta G, Christensen ND, Hu J, Choudhury ZS, Azeem A, Jester JV, Nesburn AB, Wechsler SL, BenMohamed L.

J Immunol. 2010 Mar 1;184(5):2561-71. doi: 10.4049/jimmunol.0902322. Epub 2010 Feb 1.


DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Vojnov L, Bean AT, Peterson EJ, Chiuchiolo MJ, Sacha JB, Denes FS, Sandor M, Fuller DH, Fuller JT, Parks CL, McDermott AB, Wilson NA, Watkins DI.

Vaccine. 2011 Oct 6;29(43):7483-90. doi: 10.1016/j.vaccine.2011.07.048. Epub 2011 Aug 10.


Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.

Kim S, Li L, McMurtrey CP, Hildebrand WH, Weidanz JA, Gillanders WE, Diamond MS, Hansen TH.

J Immunol. 2010 Apr 15;184(8):4423-30. doi: 10.4049/jimmunol.0903955. Epub 2010 Mar 8.


Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.

Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.

J Immunol. 2010 Sep 15;185(6):3445-55. doi: 10.4049/jimmunol.1001397. Epub 2010 Aug 23.


A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.

Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M.

Cancer Immunol Immunother. 2011 Sep;60(9):1333-46. doi: 10.1007/s00262-011-1030-6. Epub 2011 Jun 1.


Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.


Identification of conserved subdominant HIV Type 1 CD8(+) T Cell epitopes restricted within common HLA Supertypes for therapeutic HIV Type 1 vaccines.

Karlsson I, Kløverpris H, Jensen KJ, Stryhn A, Buus S, Karlsson A, Vinner L, Goulder P, Fomsgaard A.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1434-43. doi: 10.1089/AID.2012.0081. Epub 2012 Aug 14.


High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection.

Keane NM, Roberts SG, Almeida CA, Krishnan T, Chopra A, Demaine E, Laird R, Tschochner M, Carlson JM, Mallal S, Heckerman D, James I, John M.

Immunol Cell Biol. 2012 Feb;90(2):224-34. doi: 10.1038/icb.2011.34. Epub 2011 May 17.


PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity.

Oyarzún P, Ellis JJ, Bodén M, Kobe B.

BMC Bioinformatics. 2013 Feb 14;14:52. doi: 10.1186/1471-2105-14-52.


In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.

Pratheek BM, Suryawanshi AR, Chattopadhyay S, Chattopadhyay S.

Infect Genet Evol. 2015 Apr;31:118-26. doi: 10.1016/j.meegid.2015.01.017. Epub 2015 Jan 31.


Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ.

Blood. 2002 Nov 15;100(10):3681-9. Epub 2002 Jul 12.


Computer aided subunit vaccine design against pathogenic Leptospira serovars.

Umamaheswari A, Pradhan D, Hemanthkumar M.

Interdiscip Sci. 2012 Mar;4(1):38-45. doi: 10.1007/s12539-012-0118-9. Epub 2012 Mar 6.


Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.

Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagné F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF.

Arthritis Res. 2000;2(2):154-64. Epub 2000 Feb 7.


Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).

Liao ZL, Tang XD, Lü MH, Wu YY, Cao YL, Fang DC, Yang SM, Guo H.

Cancer Sci. 2012 Nov;103(11):1920-8. doi: 10.1111/j.1349-7006.2012.02410.x. Epub 2012 Sep 28.


From ZikV genome to vaccine: in silico approach for the epitope-based peptide vaccine against Zika virus envelope glycoprotein.

Alam A, Ali S, Ahamad S, Malik MZ, Ishrat R.

Immunology. 2016 Dec;149(4):386-399. doi: 10.1111/imm.12656. Epub 2016 Sep 7.


Supplemental Content

Support Center